Literature DB >> 8514611

Effect of accessory cells on stimulation of murine T-cell leukemia with antibodies to the CD3/T cell antigen receptor complex.

R Suto1, H Udono, A Yamamoto, H Shiku, E Nakayama.   

Abstract

Stimulation of EL4 and RL male 1 leukemia cells in vitro with immobilized anti-CD3 epsilon monoclonal antibody (mAb) (145-2C11) or anti-TCR beta mAb (H57-597) in the absence of accessory cells induced interleukin-2 (IL-2) production, and caused growth inhibition. The growth inhibition was, however, transient and the tumors started to grow again within 5 days in immobilizing plates treated with antibodies at concentrations of 2.5-100 micrograms/ml. Addition of mitomycin C-treated accessory cells to the culture inhibited IL-2 production and resulted in augmented and persistent growth inhibition. No recovery of tumor growth was observed. Furthermore, DNA from EL4 and RL male 1 leukemia cells stimulated with anti-CD3/TCR mAbs was fragmented even in the absence of accessory cells, but fragmentation was much greater in the presence of accessory cells. Marginal and high expression of the bcl-2 gene were observed in EL4 and RL male 1, respectively, indicating that apoptosis of these leukemias mediated by signalling through the CD3/TCR complex has no direct relationship with expression of the bcl-2 gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514611      PMCID: PMC5919313          DOI: 10.1111/j.1349-7006.1993.tb00155.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  31 in total

1.  Susceptibility to cell death is a dominant phenotype: triggering of activation-driven T-cell death independent of the T-cell antigen receptor complex.

Authors:  G Nickas; J Meyers; L D Hebshi; J D Ashwell; D P Gold; B Sydora; D S Ucker
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

2.  In vivo administration of anti-CD3 prevents malignant progressor tumor growth.

Authors:  J D Ellenhorn; R Hirsch; H Schreiber; J A Bluestone
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

3.  Anti-idiotypic antibodies against UV-induced tumor-specific CTL clones. Preparation in syngeneic combination.

Authors:  K Kuribayashi; C Tanaka; Y Matsubayashi; T Masuda; H Udono; M Abe; E Nakayama; H Shiku
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

4.  Establishment and characterization of BALB/c lymphoma lines with B cell properties.

Authors:  K J Kim; C Kanellopoulos-Langevin; R M Merwin; D H Sachs; R Asofsky
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

5.  Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules.

Authors:  M Merćep; J A Bluestone; P D Noguchi; J D Ashwell
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

6.  Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

Authors:  J D Ellenhorn; H Schreiber; J A Bluestone
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

7.  CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.

Authors:  M Mieno; R Suto; Y Obata; H Udono; T Takahashi; H Shiku; E Nakayama
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

8.  Cell growth cycle block of T cell hybridomas upon activation with antigen.

Authors:  J D Ashwell; R E Cunningham; P D Noguchi; D Hernandez
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

9.  Studies in antibody response of mice to tumour inoculation.

Authors:  P A GORER
Journal:  Br J Cancer       Date:  1950-12       Impact factor: 7.640

10.  Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.